Key Points
- Mineralys Therapeutics insider David Malcom Rodman sold 14,056 shares on May 13 at an average price of $28.58, totaling about $401,720. The sale was made under a pre-arranged Rule 10b5-1 plan, and his ownership fell 18.14% to 63,443 shares.
- Rodman has been actively trimming his stake with multiple recent sales in April and May, including several larger transactions of 6,348 and 14,058 shares. The repeated selling suggests a sustained pattern of insider disposals rather than a one-off trade.
- Mineralys shares were down 8.2% to open at $26.86, even though the company recently reported quarterly earnings that beat analyst expectations. Analyst sentiment remains mixed but generally positive, with a consensus Moderate Buy and an average price target of $49.33.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 2,171 shares of the business's stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $29.71, for a total transaction of $64,500.41. Following the sale, the insider directly owned 69,792 shares of the company's stock, valued at approximately $2,073,520.32. The trade was a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.36, for a total transaction of $186,377.28.
- On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48.
- On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $31.33, for a total transaction of $13,033.28.
- On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68.
- On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32.
- On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.59, for a total transaction of $11,505.03.
Mineralys Therapeutics Stock Down 8.2%
MLYS opened at $26.86 on Thursday. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -13.10 and a beta of 0.49. Mineralys Therapeutics, Inc. has a twelve month low of $12.59 and a twelve month high of $47.65. The company's 50-day moving average price is $27.12 and its two-hundred day moving average price is $32.76.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.04. As a group, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a "buy" rating on the stock. Jefferies Financial Group reiterated a "hold" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research note on Friday, March 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the company a "buy" rating in a research note on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Mineralys Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $49.33.
Read Our Latest Stock Report on MLYS
Institutional Trading of Mineralys Therapeutics
A number of institutional investors have recently modified their holdings of MLYS. State Street Corp lifted its stake in shares of Mineralys Therapeutics by 144.4% during the 4th quarter. State Street Corp now owns 3,184,999 shares of the company's stock valued at $115,584,000 after buying an additional 1,881,976 shares in the last quarter. Farallon Capital Management LLC bought a new stake in Mineralys Therapeutics during the 3rd quarter worth approximately $63,442,000. Price T Rowe Associates Inc. MD increased its holdings in Mineralys Therapeutics by 6,097.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company's stock worth $48,089,000 after acquiring an additional 1,303,737 shares during the period. Holocene Advisors LP bought a new stake in Mineralys Therapeutics during the 3rd quarter worth approximately $45,708,000. Finally, Janus Henderson Group PLC increased its holdings in Mineralys Therapeutics by 6,012.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company's stock worth $44,005,000 after acquiring an additional 1,193,417 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
